Novel biomarkers in heart failure: An overview

Biomarkers in Medicine

Volumn 3, Issue 5, 2009, Pages 453-463

  Dalzell, Jonathan R ^a   Jackson, Colette E ^a   McDonagh, Theresa A ^b   Gardner, Roy S ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

Author keywords

Acutely decompensated heart failure; Biomarker; Chronic heart failure; Novel; Pathophysiology

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APELIN; BIOLOGICAL MARKER; CARDIOTROPHIN 1; CHROMOGRANIN A; COPEPTIN; CYSTATIN C; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; HEART TYPE FATTY ACID BINDING PROTEIN; INTERLEUKIN 6; MYOSIN LIGHT CHAIN 1; OSTEOPONTIN; PENTRAXIN 3; PROADRENOMEDULLIN; SPHINGOMYELIN PHOSPHODIESTERASE; ST2 PROTEIN; SURFACTANT PROTEIN B; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; UNCLASSIFIED DRUG; UROCORTIN;

ACUTE HEART FAILURE; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DISEASE SEVERITY; HEART ASSIST DEVICE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; NONHUMAN; PREDICTION; PROGNOSIS; REVIEW;

EID: 70450255332     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.42     Document Type: Review

References (141)

1. Mosterd A, Hoes AW: Clinical epidemiology of heart failure. Heart 93, 1137-1146 (2007).
2. Gardner RS, Chong KS, McDonagh TA: B-type natriuretic peptides in heart failure. Biomark. Med. 1(2), 243-250 (2007).
3. Gegenhuber A, Struck J, Poelz W et al.: Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin. Chem. 52(5), 827-831 (2006). (Pubitemid 43673260)
4. Elmas E, Brueckmann M, Lang S et al.: Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease. Int. J. Cardiol. 128(2), 244-249 (2008). (Pubitemid 352033584)
5. Gegenhuber A, Struck J, Dieplinger B et al.: Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J. Card. Fail. 13(1), 42-49 (2007). ■■ Large study demonstrating the prognostic power of midregional pro-atrial natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM) and copeptin in acute destabilized heart failure (ADHF). (Pubitemid 46343794)
6. von Haehling S, Jankowska EA, Morgenthaler NG et al.: Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J. Am. Coll. Cardiol. 50(20), 1973-1980 (2007). ■■ First study to demonstrate the prognostic power of MR-proANP in a large group of patients with chronic heart failure (CHF).
7. Moertl D, Berger R, Struck J et al.: Comparison of midregional pro-ANP and B-type natriuretic peptides in chronic heart failure. J. Am. Coll. Cardiol. 53(19), 1783-1790 (2009). ■■ Large study confirming the prognostic power of MR-proANP in CHF and suggesting that it adds information to that provided by the B-type natriuretic peptides (BNPs).
8. Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJ: The clinical relevance of adrenomedullin: a promising profile? Pharmacol. Ther. 103(3), 179-201 (2004).
9. Pousset F, Masson F, Chavirovskaia O et al.: Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur. Heart J. 21(12), 1009-1014 (2000). (Pubitemid 30312090)
10. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin. Chem. 51(10), 1823-1829 (2005).
11. Elmas E, Lang S, Dempfle CE et al.: Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction. Int. J. Cardiol. 128(1), 107-111 (2008). (Pubitemid 351905763)
12. Khan SQ, O'Brien RJ, Struck J et al.: Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J. Am. Coll. Cardiol. 49(14), 1525-1532 (2007).
13. Adlbrecht C, Hülsmann M, Strunk G et al.: Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur. J Heart Fail. 11(4), 361-366 (2009). ■■ Large study demonstrating the prognostic power of copeptin in CHF.
14. Finley JJ 4th, Konstam MA, Udelson JE: Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 118(4), 410-421 (2008).
15. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN: Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. 1(6), 1385-1390 (1983).
16. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 52(1), 112-119 (2006). (Pubitemid 43032474)
17. Khan SQ, Dhillon OS, O'Brien RJ et al.: C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115(16), 2103-2110 (2007).
18. Kelly D, Squire IB, Khan SQ et al.: C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J. Card. Fail. 14(9), 739-745 (2008).
19. Voors AA, von Haehling S, Anker SD et al.: C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur. Heart J. 30(10), 1187-1194 (2009).
20. Stoiser B, Mörtl D, Hülsmann M et al.: Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur. J. Clin. Invest. 36(11), 771-778 (2006). (Pubitemid 44569965)
21. Neuhold S, Huelsmann M, Strunk G et al.: Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J. Am. Coll. Cardiol. 52(4), 266-272 (2008). ■■ Large study suggesting that copeptin provides superior prognostic information to the BNPs in CHF. (Pubitemid 351957847)
22. Helle KB: The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol. Rev. Camb. Philos. Soc. 79(4), 769-794 (2004).
23. Pieroni M, Corti A, Tota B et al.: Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur. Heart J. 28(9), 1117-1127 (2007). (Pubitemid 47343865)
24. Taupenot L, Harper KL, O'Connor DT: The chromogranin-secretogranin family. N. Engl. J. Med. 348(12), 1134-1149 (2003).
25. Aardal S, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G: Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J. Neuroendocrinol. 5(4), 405-412 (1993). (Pubitemid 23243499)
26. Imbrogno S, Angelone T, Corti A, Adamo C, Helle KB, Tota B: Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen. Comp. Endocrinol. 139(1), 20-28 (2004). (Pubitemid 39345610)
27. Corti A, Mannarino C, Mazza R, Angelone T, Longhi R, Tota B: Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7-57 peptide act as cardiostatins on the isolated working frog heart. Gen. Comp. Endocrinol. 136(2), 217-224 (2004). (Pubitemid 38340784)
28. Tota B, Mazza R, Angelone T et al.: Peptides from the N-terminal domain of chromogranin A (vasostatins) exert negative inotropic effects in the isolated frog heart. Regul. Pept. 114(2-3), 123-130 (2003). (Pubitemid 36773876)
29. Cerra MC, De Iuri L, Angelone T, Corti A, Tota B: Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res. Cardiol. 101(1), 43-52 (2006). (Pubitemid 43323431)
30. Angelone T, Quintieri AM, Brar BK et al.: The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 149(10), 4780-4793 (2008).
31. Mazza R, Gattuso A, Mannarino C et al.: Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am. J Physiol. Heart Circ. Physiol. 295(1), H113-H122 (2008).
32. Schulze PC: Chromogranin A: friend or foe of the failing myocardium? Eur. Heart J. 28(9), 1052-1053 (2007).
33. Ratti S, Curnis F, Longhi R et al.: Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J. Biol. Chem. 275(38), 29257-29263 (2000). (Pubitemid 32043794)
34. Soriano JV, Pepper MS, Taupenot L, Bader MF, Orci L, Montesano R: Chromogranin A alters ductal morphogenesis and increases deposition of basement membrane components by mammary epithelial cells in vitro. Biochem. Biophys. Res. Commun. 259(3), 563-568 (1999). (Pubitemid 29335573)
35. Ceconi C, Ferrari R, Bachetti T et al.: Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur. Heart J. 23(12), 967-974 (2002).
36. Dieplinger B, Gegenhuber A, Struck J et al.: Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin. Chim. Acta 400(1-2), 91-96 (2009).
37. Boriani G, Regoli F, Saporito D et al.: Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response. Peptides 27(7), 1776-1786 (2006). (Pubitemid 43880376)
38. Wohlschlaeger J, von Winterfeld M, Milting H et al.: Decreased myocardial chromogranin an expression and colocalization with brain natriuretic peptide during reverse cardiac remodeling after ventricular unloading. J. Heart Lung Transplant. 27(4), 442-449 (2008).
39. Kleinz MJ, Davenport AP: Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul. Pept. 118, 119-125 (2004).
40. O'Dowd BF, Heiber M, Chan A et al.: A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136(1-2), 355-360 (1993). (Pubitemid 24049270)
41. Lee DK, Cheng R, Nguyen T et al.: Characterization of apelin, the ligand for the APJ receptor. J. Neurochem. 74(1), 34-41(2000). (Pubitemid 30012752)
42. Tatemoto K, Takayama K, Zou MX et al.: The novel peptide apelin lowers blood pressure via a nitric oxide dependent mechanism. Regul. Pept. 99, 87-92 (2001). (Pubitemid 32522535)
43. Jia YX, Lu ZF, Zhang J et al.: Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 28, 2023-2029 (2007). (Pubitemid 47419100)
44. Japp AG, Cruden NL, Amer DA et al.: Vascular effects of apelin in vivo in man. J. Am. Coll. Cardiol. 52(11), 908-913 (2008).
45. De Mota N, Reaux-Le Goazigo A, El Messari S et al.: Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc. Natl Acad. Sci. USA 101(28), 10464-10469 (2004).
46. Hus-Citharel A, Bouby N, Frugière A, Bodineau L, Gasc JM, Llorens-Cortes C: Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int. 74(4), 486-494 (2008).
47. Ernst KV, Ashley EA, Charo D et al.: Apelin regulates cardiac contractility and rescues neurohormonal heart failure. Circulation 114 (2006) (Abstract II-66).
48. Szokodi I, Tavi P, Foldes G et al.: Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates contractility. Circ. Res. 91, 434-1400 (2002).
49. Farkasfalvi K, Stagg MA, Coppen SR et al.: Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem. Biophys. Res. Comm. 357, 889-895 (2007).
50. Jia YX, Pan CS, Zhang J et al.: Apelin protects myocardial injury induced by isoproterenol in rats. Regul. Pept. 133(1-3), 147-154 (2006).
51. Berry MF, Pirolli TJ, Jayasankar V et al.: Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110(Suppl. 11), 187-193 (2004).
52. Ashley EA, Powers J, Chen M et al.: The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc. Res. 65(1), 73-82 (2005).
53. Kuba K, Zhang L, Imai Y et al.: Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload. Circ. Res. 101(4), E32-E42 (2007).
54. Weir RA, Chong KS, Dalzell JR et al.: Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur. J. Heart Fail. 11(6), 551-558 (2009).
55. van Kimmenade RR, Januzzi JL Jr, Ellinor PT et al.: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 48(6), 1217-1224 (2006). ■ First study to demonstrate the prognostic power of galectin-3 in ADHF.
56. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA: Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur. J. Heart Fail. 8(4), 355-360 (2006). ■ First description of reduced plasma apelin levels in CHF.
57. Chen MM, Ashley EA, Deng DX et al.: Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108(12), 1432-1439 (2003).
58. Francia P, Salvati A, Balla C et al.: Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur. J. Heart Fail. 9(3), 306-309 (2007).
59. Goetze JP, ReCHFeld JF, Carlsen J et al.: Apelin: a new plasma marker of cardiopulmonary disease. Regul. Pept. 133(1-3), 134-138 (2006).
60. Földes G, Horkay F, Szokodi I et al.: Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem. Biophys. Res. Commun. 308(3), 480-485 (2003).
61. Mullens W, Bartunek J, Wilson Tang WH et al.: Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm 5(1), 52-59 (2008).
62. Burnett JC Jr: Urocortin, advancing the neurohumoral hypothesis of heart failure. Circulation 112(23), 3544-3546 (2005).
63. Parkes DG, Vaughan J, Rivier J, Vale W, May CN: Cardiac inotropic actions of urocortin in conscious sheep. Am. J. Physiol. 272(5 Pt 2), H2115-H2122 (1997).
64. Chen ZW, Huang Y, Yang Q, Li X, Wei W, He GW: Urocortin-induced relaxation in the human internal mammary artery. Cardiovasc. Res. 65(4), 913-920 (2005).
65. Sanz E, Monge L, Fernández N et al.: Relaxation by urocortin of human saphenous veins. Br. J. Pharmacol. 136(1), 90-94 (2002).
66. Nishikimi T, Miyata A, Horio T et al.: Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am. J Physiol. Heart Circ. Physiol. 279(6), H3031-H3039 (2000).
67. Ikeda K, Tojo K, Sato S et al.: Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem. Biophys. Res. Commun. 250(2), 298-304 (1998).
68. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM: Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur. Heart J. 26(19), 2055-2062 (2005).
69. Rademaker MT, Cameron VA, Charles CJ, Richards AM: Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 112(23), 3624-3632 (2005).
70. Rademaker MT, Cameron VA, Charles CJ, Richards AM: Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur. Heart J. 27(17), 2088-2098 (2006).
71. Bale TL, Hoshijima M, Gu Y et al.: The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc. Natl Acad. Sci. USA 101(10), 3697-3702 (2004).
72. Rademaker MT, Charles CJ, Richards AM: Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure. Am. J. Physiol. Heart Circ. Physiol. 293(3), H1536-H1544 (2007).
73. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE: Plasma urocortin in human systolic heart failure. Clin. Sci. 106(4), 383-388 (2004). ■ First description of urocortin levels in humans with CHF.
74. Crane FL, Hatefi Y, Lester RL, Widmer C: Isolation of a quinone from beef heart mitochondria. Biochim. Biophys. Acta 25(1), 220-221 (1957).
75. 10. Proc. Natl Acad. Sci. USA 82(3), 901-904 (1985).
76. 10 in CHF.
77. 10 on systolic function in patients with chronic heart failure. J. Card. Fail. 12(6), 464-472 (2006).
78. 10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio" - a multinational trial. Biofactors 18(1-4), 79-89 (2003).
79. Hopkins TA, Ouchi N, Shibata R, Walsh K: Adiponectin actions in the cardiovascular system. Cardiovasc. Res. 74(1), 11-18 (2007).
80. Fujioka D, Kawabata K, Saito Y et al.: Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am. J Physiol. Heart Circ. Physiol. 290(6), H2409-H2416 (2006).
81. Dieplinger B, Gegenhuber A, Poelz W, Haltmayer M, Mueller T: Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin. Biochem. 42(10-11), 1190-1193(2009).
82. Tanaka T, Tsutamoto T, Sakai H et al.: Effect of atrial natriuretic peptide on adiponectin in patients with heart failure. Eur. J. Heart Fail. 10(4), 360-366 (2008).
83. Kistorp C, Faber J, Galatius S et al.: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112(12), 1756-1762 (2005).
84. McEntegart MB, Awede B, Petrie MC et al.: Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur. Heart J. 28(7), 829-835 (2007). ■ First description of the correlation between BNP, adiponectin and cachexia in CHF.
85. Schaap FG, van der Vusse GJ, Glatz JF: Fatty acid-binding proteins in the heart. Mol. Cell. Biochem. 180(1-2), 43-51 (1998).
86. Setsuta K, Seino Y, Ogawa T, Arao M, Miyatake Y, Takano T: Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am. J. Med. 113(9), 717-722 (2002).
87. Niizeki T, Takeishi Y, Arimoto T et al.: Serum heart-type fatty acid binding protein predicts cardiac events in elderly patients with chronic heart failure. J. Cardiol. 46(1), 9-15 (2005).
88. Komamura K, Sasaki T, Hanatani A et al.: Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy. Heart 92(5), 615-618 (2006).
89. Niizeki T, Takeishi Y, Arimoto T et al.: Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure. Circ. J. 69(8), 922-927 (2005). (Pubitemid 41124259)
90. Niizeki T, Takeishi Y, Arimoto T et al.: Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J. Card. Fail. 13(2), 120-127 (2007). (Pubitemid 46467389)
91. Niizeki T, Takeishi Y, Arimoto T et al.: Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ. J. 72(1), 109-114 (2008).
92. Hansen MS, Stanton EB, Gawad Y et al.: Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Am. J. Cardiol. 90(9), 969-973 (2002). (Pubitemid 35232621)
93. Sugiura T, Takase H, Toriyama T, Goto T, Ueda R, Dohi Y: Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J. Card. Fail. 11(7), 504-509 (2005). (Pubitemid 41399889)
94. Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91(11), 988-998 (2002).
95. Yanagisawa K, Tsukamoto T, Takagi T, Tominaga S: Murine ST2 gene is a member of the primary response gene family induced by growth factors. FEBS Lett. 302(1), 51-53 (1992).
96. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN: T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 191(6), 1069-1076 (2000).
97. Weinberg EO, Shimpo M, De Keulenaer GW et al.: Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106(23), 2961-2966 (2002). (Pubitemid 35424749)
98. Schmitz J, Owyang A, Oldham E et al.: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 23(5), 479-490 (2005). (Pubitemid 41587888)
99. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT: IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117(6), 1538-1549 (2007). (Pubitemid 46871338)
100. Sabatine MS, Morrow DA, Higgins LJ et al.: Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117(15), 1936-1944 (2008).
101. Boisot S, Beede J, Isakson S et al.: Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail. 14(9), 732-738 (2008).
102. Rehman SU, Mueller T, Januzzi JL Jr: Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 52(18), 1458-1465 (2008). ■■ Demonstration of the prognostic power of serum soluble ST2 in ADHF.
103. Januzzi JL Jr, Peacock WF, Maisel AS et al.: Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol. 50(7), 607-613 (2007).
104. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M: Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin. Chem. 54(4), 752-756 (2008). (Pubitemid 351573718)
105. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT: Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107(5), 721-726 (2003). ■■ First demonstration of the prognostic power of serum soluble ST2 in CHF. (Pubitemid 36222600)
106. Kempf T, Eden M, Strelau J et al.: The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ. Res. 98(3), 351-360 (2006).
107. Xu J, Kimball TR, Lorenz JN et al.: GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ. Res. 98(3), 342-350 (2006). (Pubitemid 43755330)
108. Kempf T, von Haehling S, Peter T et al.: Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol. 50(11), 1054-1060 (2007). (Pubitemid 47348231)
109. Garlanda C, Bottazzi B, Bastone A, Mantovani A: Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition and female fertility. Annu. Rev. Immunol. 23, 337-366 (2005). (Pubitemid 40563173)
110. Latini R, Maggioni AP, Peri G et al.: Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110(16), 2349-2354 (2004). (Pubitemid 39407338)
111. Suzuki S, Takeishi Y, Niizeki T et al.: Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am. Heart J. 155(1), 75-81 (2008). (Pubitemid 350234768)
112. Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K: Prognostic value of pentraxin 3 in patients with chronic heart failure. Int. J. Cardiol. 130(1), 19-22 (2008).
113. Xie Z, Pimental DR, Lohan S et al.: Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: role of p42/44 mitogen-activated protein kinase and reactive oxygen species. J. Cell. Physiol. 188, 132-138 (2001). (Pubitemid 32476503)
114. Singh K, Sirokman G, Communal C et al.: Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 33(2), 663-670 (1999). (Pubitemid 29091644)
115. Xie Z, Singh M, Singh K: Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice. Hypertension 44(6), 826-831 (2004). (Pubitemid 39577407)
116. Kramer F, Sandner P, Klein M, Krahn T: Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat. Biomarkers 13(3), 270-281 (2008). (Pubitemid 351552473)
117. Stawowy P, Blaschke F, Pfautsch P et al.: Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur. J. Heart Fail. 4(2), 139-146 (2002). (Pubitemid 34233499)
118. Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K: Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur. J. Heart Fail. 7(5), 755-762 (2005). (Pubitemid 41125889)
119. Rosenberg M, Zugck C, Nelles M et al.: Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ. Heart Fail. 15(4), 43-49 (2008).
120. Marathe S, Schissel SL, Yellin MJ et al.: Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J. Biol. Chem. 273(7), 4081-4088 (1998). (Pubitemid 28103275)
121. Hernandez OM, Discher DJ, Bishopric NH, Webster KA: Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ. Res. 86(2), 198-204 (2000).
122. Oral H, Dorn GW 2nd, Mann DL: Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-α in the adult mammalian cardiac myocyte. J. Biol. Chem. 272(8), 4836-4842 (1997). (Pubitemid 27090030)
123. Doehner W, Bunck AC, Rauchhaus M et al.: Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur. Heart J. 28(7), 821-828 (2007). (Pubitemid 47343591)
124. Pennica D, Swanson TA, Shaw KJ et al.: Human cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization. Cytokine 8(3), 183-189 (1996). (Pubitemid 26111115)
125. Pemberton CJ, Raudsepp SD, Yandle TG, Cameron VA, Richards AM: Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc. Res. 68(1), 109-117 (2005).
126. Zolk O, Engmann S, Münzel F, Krajcik R: Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am. J. Physiol. Endocrinol. Metab. 288(6), E1214-E1221 (2005). (Pubitemid 40726809)
127. Jin H, Yang R, Keller GA et al.: In vivo effects of cardiotrophin-1. Cytokine 8(12), 920-926 (1996).
128. Tsutamoto T, Wada A, Maeda K et al.: Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 38(5), 1485-1490 (2001).
129. Tsutamoto T, Asai S, Tanaka T et al.: Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure. Eur. J. Heart Fail. 9(10), 1032-1037 (2007). (Pubitemid 47451817)
130. Li Y, Komai-Koma M, Gilchrist DS et al.: Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation. J. Immunol. 181(4), 2781-2789 (2008).
131. Sharma UC, Pokharel S, van Brakel TJ et al.: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110(19), 3121-3128 (2004). (Pubitemid 39492008)
132. Sharma U, Rhaleb NE, Pokharel S et al.: Novel anti-inflammatory mechanisms of N-acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am. J Physiol. Heart Circ. Physiol. 294(3), H1226-H1232 (2008).
133. Milting H, Ellinghaus P, Seewald M et al.: Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J. Heart Lung Transplant. 27(6), 589-596 (2008). (Pubitemid 351715387)
134. Abrahamson M, Olafsson I, Palsdottir A et al.: Structure and expression of the human cystatin C gene. Biochem. J. 268(2), 287-294 (1990). (Pubitemid 20193964)
135. Lassus J, Harjola VP, Sund R et al.: Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur. Heart J. 28(15), 1841-1847 (2007).
136. Ix JH, Shlipak MG, Chertow GM, Whooley MA: Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115(2), 173-179 (2007).
137. Arimoto T, Takeishi Y, Niizeki T et al.: Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. J. Card. Fail. 11(8), 595-601 (2005). (Pubitemid 41463730)
138. Shlipak MG, Katz R, Fried LF et al.: Cystatin-C and mortality in elderly persons with heart failure. J. Am. Coll. Cardiol. 45(2), 268-271 (2005). (Pubitemid 40094736)
139. De Pasquale CG: Surfactant protein-B in chronic heart failure: an insight to the alveolocapillary barrier. Rev. Esp. Cardiol. 62(2), 117-119 (2009).
140. De Pasquale CG, Arnolda LF, Doyle IR, Grant RL, Aylward PE, Bersten AD: Prolonged alveolocapillary barrier damage after acute cardiogenic pulmonary edema. Crit. Care Med. 31(4), 1060-1067 (2003).
141. De Pasquale CG, Arnolda LF, Doyle IR, Aylward PE, Chew DP, Bersten AD: Plasma surfactant protein-B: a novel biomarker in chronic heart failure. Circulation 110(9), 1091-1096 (2004).